Clinical Colorectal Cancer
Издатель: Elsevier · ISSN 1533-0028 · 43 статей
- Real-world use of encorafenib plus cetuximab after prior systemic therapy in patients with BRAFV600E-mutant metastatic colorectal cancer: a pooled analysis of European observational studies
- Brain Metastasis From Anal Canal Squamous Cell Carcinoma: A Rare Case Report and Systematic Review
- Circulating Tumor DNA as a Biomarker for Recurrence After Curative Resection of Colorectal Cancer Liver Metastases: A Systematic Review and Meta-Analysis
- Late-line Systemic Therapy in Metastatic Colorectal Cancer: A Narrative Review and Australian Expert Perspective
- The Role of Systemic Chemotherapy to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients With Appendiceal Cancers
- Randomized phase III Study of Adding Paclitaxel to Chemoradiotherapy With Capecitabine and Mitomycin C in Squamous Cell Anal Carcinoma
- Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Colorectal Cancer: Results From the Phase II LEAP-005 Study
- Consistency of Radiological Staging in Resectable Mismatch-Repair Proficient Colon Cancer: An Interobserver Agreement Study
- Phase Ib Study to Assess the Safety of Neoadjuvant Trifluridine/Tipiracil With Concurrent Radiation in Resectable Stage II/III Rectal Cancer: The FIERCE Study
- The Impact of Surgical Resection in Early Onset Colorectal Cancer Patients With Liver Limited Disease
- Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer
- Incidence and Risk Factors of Non-neutropenic Enterocolitis With Adjuvant Capecitabine and Oxaliplatin Chemotherapy in Colorectal Cancer
- Bowel Stenosis Following Immunotherapy in dMMR Colorectal Cancer: A Case Series
- Successful Encorafenib and Cetuximab Re-Challenge Combined With Nivolumab in BRAF V600E Mutated, Mismatch-Repair-Proficient Metastatic Colorectal Cancer – A Case Report From the AGMT mCRC Registry
- AZUR-4, a Phase 2, Open Label, Randomized Study of Neoadjuvant Dostarlimab Plus CAPEOX Versus CAPEOX in Previously Untreated T4N0 or Stage III Mismatch Repair Proficient/Microsatellite Stable Resectable Colon Cancer
- Durable Responses to Immunotherapy in dMMR/MSI-H Metastatic Colorectal Cancer Patients With Poor Performance Status
- Late Toxicity, Cohort Continuity, and Endpoint Transparency in Triplet Chemoradiotherapy for Anal Cancer
- Efficacy and Safety of Immune Checkpoint Inhibitor-Based Neoadjuvant Therapy Combinations in Proficient Mismatch Repair/Microsatellite Stable Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis
- Interobserver Agreement and Radiological–Pathological Concordance of CT Staging in Localized Colon Cancer
- Editorial Board
- Table of contents
- Time to Double Down: Dual Immunotherapy as the Best Bet for Treatment of Microsatellite Instability-High Metastatic Colorectal Cancer
- Optimizing Systemic Therapy in Advanced Gastrointestinal Malignancies: Strategies to Minimize Toxicity and Maximize Tolerability
- Dual CTLA-4/PD-1 Blockade Versus Anti–PD-1 in MSI-H Metastatic Colorectal Cancer: Early Survival Benefit and Exploratory Clinical Predictors
- Detection of Polyps in Colon Capsule Endoscopy and Impact of Colonic Transit Time
- Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal Cancer
- Discordant Dynamics Between Absolute ctDNA and Tumor Fraction During Treatment Monitoring in Metastatic Colorectal Cancer: Evidence of a Dilution Phenomenon
- Fruquintinib or Regorafenib? A Weighted Toxicity Score Analysis to Facilitate Better Discussions on Toxicity and Benefits in Later-line Colorectal Cancer Treatment
- Resource Use and Costs of the Low-risk Arm of a Risk-stratified Colorectal Cancer Screening Approach Based on Previous Negative FIT Values: Comparative Analyses With the Standard Approach
- Comparing Quality of Life in Rectal Cancer Survivors Managed With Watch-and-Wait Versus Surgery